Bay Street News, March 26th, 2025

EL MONTE, Calif., March 26, 2025 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer […]

– RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary […]

FORT MYERS, Fla., March 26, 2025 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announced that […]

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — The Nasdaq Stock Market announced today that it will delist the Class […]

Fourth quarter results compared to prior year: Orders grew 9%, driven by 12% broad-based growth in the Americas Gross margin […]

Full Year Revenues up in each of ACH & Complementary Services, Card and Output Solutions Business Units Record Full Year […]

PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company […]

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total […]

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial […]

ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative […]